Nektar Therapeutics (NKTR)

17.54 +0.36  +2.10% NASDAQ Oct 23, 20:00 USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
11/06/2020 17:00 EST Misc Nektar Therapeutics Inc Third Quarter Earnings Conference Call for 2020
11/06/2020 Earnings Nektar Therapeutics Inc Third Quarter Earnings for 2020 Release
08/06/2020 17:00 EDT Misc Nektar Therapeutics Second Quarter Earnings Conference Call for 2020
08/06/2020 Earnings Nektar Therapeutics Second Quarter Earnings Result for 2020
06/17/2020 14:00 PDT Misc Nektar Therapeutics Annual General Meeting for 2019
05/07/2020 17:00 EDT Misc Nektar Therapeutics First Quarter Earnings Conference Call for 2020
05/07/2020 Earnings Nektar Therapeutics First Quarter Earnings Result for 2020
02/27/2020 17:00 EST Misc Nektar Therapeutics Inc Fourth Quarter Earnings Conference Call for 2019
02/27/2020 Earnings Nektar Therapeutics Inc Fourth Quarter Earnings Results for 2019
11/06/2019 17:00 EST Misc Nektar Therapeutics Inc Third Quarter Earnings Conference Call for 2019
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.nektar.com
  • Investor Relations URL: http://ir.nektar.com/
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Blend
  • Next Earnings Release: Nov. 06, 2020
  • Last Earnings Release: Aug. 06, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Nektar Therapeutics is a San Francisco-based emerging biotechnology company specializing in PEGylation technology. Its portfolio includes PEGylated biologics in immuno-oncology, breast cancer, and autoimmune disease. The company partners with several large pharmaceutical and biotechnology companies to co-develop therapies in a range of indications, which includes a collaboration with Bristol-Myers Squibb to develop bempegaldesleukin, the firm's leading immuno-oncology candidate, in combination with Bristol's Opdivo.

Top Fund Holders

Symbol Name Weighting
GOFFX Invesco Global Opp R5 10.73%
FBT First Trust NYSE Arca Biotech ETF 3.39%
POAGX PRIMECAP Odyssey Aggressive Growth 2.79%
PILL Direxion Daily Phrmctcl&MdclBl3XShrsETF 2.72%
F0000155EV ST Healthcare Innovations 9 F RE 2.54%
CNCR Loncar Cancer Immunotherapy ETF 2.49%
XPH SPDR® S&P Pharmaceuticals ETF 1.89%
POGRX PRIMECAP Odyssey Growth 1.62%
FPHAX Fidelity® Select Pharmaceuticals Port 0.79%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.